Crossmark

Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia

Published Online: 2021-07-22

Published Print: 2022-02

Authors

Parambil, Joseph G.

Gossage, James R.

McCrae, Keith R.

Woodard, Troy D.

Menon, K. V. Narayanan

Timmerman, Kasi L.

Pederson, Douglas P.

Sprecher, Dennis L.

Al-Samkari, Hanny https://orcid.org/0000-0001-6175-1383
License Information

Text and Data Mining valid from 2021-07-22

Version of Record valid from 2021-07-22
More Information

Article History

Received: 22 March 2021

Accepted: 7 July 2021

First Online: 22 July 2021

Declarations

:

: Al-Samkari: consultancy (Agios, Dova, Argenx, Rigel, Sobi, Novartis), Research Funding to Institution (Agios, Dova, Amgen). All other authors have nothing to disclose.

: This study was approved by the Institutional Review Board of the Cleveland Clinic.

Document is current